

Whole exome and transcriptome sequencing for solid and hematological cancers

Sema4 is a patient-centered health intelligence company at the vanguard of transformative healthcare. We are founded on the belief that the best way to optimize wellness is to understand individuals holistically as complex networks of molecular and clinical information. By applying AI-based algorithms to these unique networks, we derive powerful insights that drive our personalized oncology care solutions.

We are excited to announce the upcoming launch of our new whole exome sequencing (WES) and whole transcriptome sequencing (WTS) solution, designed for all solid and hematological malignancies. This test will deliver accurate, high-value insights across both somatic and germline mutations to inform:

- ✓ Diagnosis of and prognosis for solid or blood cancers
- ✓ Selection and use of targeted therapies
- ✓ Clinical trials
- ✓ Hereditary cancer contribution

Powerful insights to help personalize treatment

Our tumor/normal analysis and RNA-seq (tumor only) analysis cover these mutations based on 250x tumor coverage and 100x normal coverage across all genes, and 100M RNA reads:

- Single nucleotide polymorphisms (SNPs)
- Insertion/Deletions (INDELs)
- Copy number variants (CNVs)
- Fusions
- Relevant splice variants
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Arm- and chromosome-level aneuploidies

Samples accepted:

- ✓ FFPE
- ✓ Bone marrow
- ✓ Blood
- ✓ Saliva


Delivering differentiated patient care insights

Our unique WES/WTS offering will be delivered as an end-to-end solution through our Sema4 Provider Portal, where providers can order testing, track samples, and review results, including a dashboard view of detected genetic variants.

Results are returned in a comprehensive, easy-to-interpret report that includes patient-specific, up-to-date information on targeted therapies, clinical trials, and variants of uncertain significance.

Through our portal, providers will have access to innovative, proprietary Patient Journey and Cohort Builder tools* built on our Centrellis™ health intelligence platform, that provide an interactive timeline visualization of the patient's health journey and enable comparison to relevant patient cohorts to enable data-driven decisions about patient care.

Sema4 WES/WTS end-to-end precision oncology solution



Our team will keep you updated on the availability of this new solution.



To learn more about our oncology solutions and services, please visit sema4.com, call **833-486-6260**, or email ClientServicesOncology@sema4.com